Clinical Trials on Ehlers-Danlos Syndrome Hypermobility Type

Total 3217 results

Sanofi

Active, not recruiting

A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B

Usher's Syndrome

United States, France
Daiichi Sankyo, Inc.

Completed

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

Acute Myeloid Leukemia | Leukemia | AML | Myelodysplastic Syndrome | MDS

United States, Georgia
Moens Maarten

Recruiting

Differential Target Multiplexed Spinal Cord Stimulation (DETECT)

Failed Back Surgery Syndrome | Persistent Spinal Pain Syndrome Type 2

Belgium
Celgene

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

Myelodysplastic Syndromes (MDS) | Chronic Myelomonocytic Leukemia (CMML) | Acute Myelogenous Leukemia (AML)

United States
National Cancer Institute (NCI)

Terminated

Aflibercept in Treating Patients With Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | de Novo Myelodysplastic Syndromes

United States
National Cancer Institute (NCI)

Completed

Thalidomide in Treating Patients With Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess Blasts in Transformation | Refractory Anemia With Ringed...

United States
Columbia University
Universitat Autonoma de Barcelona; Instituto de Salud Carlos III; University... and other collaborators

Active, not recruiting

Treatment of TK2 Deficiency With Thymidine and Deoxycytidine

Thymidine Kinase 2 Deficiency | Mitochondrial DNA Depletion Syndrome 2 Myopathic Type

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome

United States
National Heart, Lung, and Blood Institute (NHLBI)
Celgene Corporation

Completed

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

Bone Marrow Diseases | Chronic Myelomonocytic Leukemia | Neutropenia | Acute Myeloid Leukemia (AML) | Myeldysplastic Syndrome (MDS)

United States
National Cancer Institute (NCI)

Completed

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia

United States
University of Texas Southwestern Medical Center

Recruiting

Brain Metabolism Observed at 7 Tesla

Glucose Metabolism Disorders | Epilepsy | Glucose Transporter Type 1 Deficiency Syndrome | Glut1 Deficiency Syndrome 1 | Glut1 Deficiency Syndrome 1, Autosomal Recessive | Glucose Transporter Protein Type 1 Deficiency Syndrome | Glucose Transport Defect

United States
University of Florida

Not yet recruiting

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Acute Myeloid Leukemia | Myelodysplastic Syndromes
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

China
Ioannis Mantzaris
AbbVie

Recruiting

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Shattuck Labs, Inc.

Recruiting

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States, Canada, United Kingdom
Novartis Pharmaceuticals

Recruiting

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

Spain, Italy, Malaysia, China, United States, Greece, Brazil
Precigen, Inc

Recruiting

PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Baylor College of Medicine
Cancer Prevention Research Institute of Texas; The Methodist Hospital Research... and other collaborators

Recruiting

Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); National Institutes of Health (NIH)

Enrolling by invitation

Pathogenesis of Hematologic Malignancies

Lymphoproliferative Disorders | Myelodysplastic Syndromes | Myeloproliferative Disorders | Acute Leukemia

United States
New York Medical College

Completed

SCT Plus Immune Therapy in Average Risk AML/MDS

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
New York Medical College

Completed

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
GlaxoSmithKline

Terminated

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Neoplasms

United States, Canada
Duke University

Completed

Adoptive Transfer of Haplo-identical DLI for AML and MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Immune System Key Ltd

Withdrawn

A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS

Myelodysplastic Syndromes | Acute Myelogenous Leukemia

Israel
M.D. Anderson Cancer Center

Completed

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

Leukemia

United States
M.D. Anderson Cancer Center
Bayer

Completed

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

Leukemia

United States
M.D. Anderson Cancer Center
Cephalon

Completed

Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
M.D. Anderson Cancer Center
Teva Pharmaceuticals USA

Terminated

Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Leukemia

United States
Masonic Cancer Center, University of Minnesota

Terminated

Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia

Myelodysplastic Syndromes | Leukemia

United States
University of Florida
The Leukemia and Lymphoma Society

Terminated

A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS

Myelodysplastic Syndromes | Leukemia, Myelogenous, Acute

United States
M.D. Anderson Cancer Center
Concordia Pharmaceuticals, Inc

Completed

FTS Study in Patients With Advanced Hematologic Malignancies

Leukemia | Myelodysplastic Syndrome

United States
Nova Scotia Health Authority

Unknown

Genetic Identification (ID) of Segmental Dysplastic Nevi

Segmental Dysplastic Nevi

Canada
University of Washington
National Cancer Institute (NCI); Bayer

Completed

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | de Novo Myelodysplastic Syndrome | Acute Biphenotypic Leukemia

United States
National Cancer Institute (NCI)

Completed

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Chronic Myelomonocytic Leukemia-2

United States
University Hospital, Clermont-Ferrand
Ministry of Health, France; French Society of Hematology

Recruiting

Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation (TMF-Allo)

Lymphoma, Non-Hodgkin | Myelodysplastic Syndromes | Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | Myeloma | Acute Leukemia in Remission | Myeloproliferative Syndrome

France
Marcela V. Maus, M.D.,Ph.D.
Kite, A Gilead Company

Active, not recruiting

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Non Hodgkin Lymphoma | Neurotoxicity | Neurotoxicity Syndromes | Cytokine Release Syndrome | Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

United States
Dana-Farber Cancer Institute
Stemline Therapeutics, Inc.

Recruiting

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
University of Nebraska
National Cancer Institute (NCI)

Withdrawn

Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Nonmalignant Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia in Remission

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Southwest Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Mesoblast International Sàrl
National Cancer Institute (NCI)

Withdrawn

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease

United States
National Cancer Institute (NCI)

Completed

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Neoplasms

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI); medac GmbH

Completed

Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Northside Hospital, Inc.

Not yet recruiting

Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
First Affiliated Hospital of Zhejiang University

Not yet recruiting

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes
First Affiliated Hospital of Zhejiang University

Recruiting

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

China
Arcellx, Inc.

Recruiting

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States

Clinical Trials on Ehlers-Danlos Syndrome Hypermobility Type

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations